PELLEPHARM
PellePharm develops patidegib, a novel hedgehog pathway inhibitor, to mitigate the tumor burden in patients with basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in phase 2 clinical trial for the treatment of sporadic BCCs.
PELLEPHARM
Social Links:
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2012-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.pellepharm.com
Total Employee:
11+
Status:
Active
Contact:
(650) 815-7404
Email Addresses:
[email protected]
Total Funding:
38.89 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Cadent Therapeutics
Cadent Therapeutics develops novel medicines that tune and modulate brain rhythms for patients with serious neurological disease.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
BridgeBio Pharma
BridgeBio Pharma investment in Series B - PellePharm
Official Site Inspections
http://www.pellepharm.com
- Host name: 92.243.74.2
- IP address: 92.243.74.2
- Location: Russia
- Latitude: 55.7386
- Longitude: 37.6068
- Timezone: Europe/Moscow
